about
Clinical development methodology for infusion-related reactions with monoclonal antibodiesA phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model.Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodiesTGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse ModelCurrent imaging strategies in rheumatoid arthritisSeverity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.In vitro cytokine release assays: reducing the risk of adverse events in man.The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients.Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.The expanding role of therapeutic antibodies.CAR T-cell therapy: toxicity and the relevance of preclinical models.Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.Successful desensitization of a patient with rituximab hypersensitivity.Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils.
P2860
Q26798184-C14E93E0-6B62-4CD1-B631-2D29714F5360Q33413739-7196F541-EF34-49D7-9C78-6F046E979DB0Q34803897-9E2AB59E-EC19-424A-897F-2B519209BB96Q35154170-8824ECF2-6155-4A6F-8AD3-42AB5D7B7FEEQ35950889-4B689268-7503-41F0-A03A-D183D6CDE3B8Q36337258-E1D8604D-46A7-4584-B2D6-C8CC25A8459CQ37064758-8A4B2481-3C83-4D10-B9A5-3F8AAEFEC86CQ37963914-0D2A7D8A-2A7D-4BDB-A6E8-11A60C6E5552Q37973651-9D63986C-3943-4328-8047-CF8C44E18251Q37987953-502ABA2F-CAF5-41A3-9DE3-25D93E327E68Q38087506-A5DB8534-D7D4-4194-9CB5-745874C09CEEQ38182645-487728B3-3E87-47CF-BF0A-271C9871E211Q38525018-BE5372A5-A7A5-40CD-9BA8-92C194343954Q38769271-B67814DB-E6CD-49E9-8C94-77E6B50B4E87Q38951943-9F6552AD-87B2-4CAD-A5CB-18A7E558F599Q40399816-B73462A3-0FBB-4E08-BDF8-4B9DC5F54981Q41341147-015E962F-1E33-4236-913B-5D2016E6333DQ41807677-55E75333-2F59-4E8B-982E-2C1CA034EF67Q49168957-8332EE7B-DF81-4D07-B0A0-8AF0C072F3A5Q49878390-554BA974-E4A2-47E3-BB7B-8534A6088127Q53564949-865694DD-0295-4DFB-9C30-9ECB80A36E48Q55216327-794C5DE0-67E8-42E9-9333-CA47C8BA6348Q55454180-D37214E0-C3C4-42B9-95C0-E3E2B738DB1C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Monoclonal antibody-induced cytokine-release syndrome.
@en
Monoclonal antibody-induced cytokine-release syndrome.
@nl
type
label
Monoclonal antibody-induced cytokine-release syndrome.
@en
Monoclonal antibody-induced cytokine-release syndrome.
@nl
prefLabel
Monoclonal antibody-induced cytokine-release syndrome.
@en
Monoclonal antibody-induced cytokine-release syndrome.
@nl
P2093
P2860
P356
P1476
Monoclonal antibody-induced cytokine-release syndrome.
@en
P2093
Esther Bouman-Thio
George Treacy
Peter J Bugelski
Ram Achuthanandam
Renold J Capocasale
P2860
P304
P356
10.1586/ECI.09.31
P577
2009-09-01T00:00:00Z